Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2020 9
2021 8
2022 88
2023 118
2024 5

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 36781188

202 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Wong CKH, et al. Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0. Lancet. 2022. PMID: 36216007 Free PMC article.
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Reis S, et al. Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2. Cochrane Database Syst Rev. 2022. PMID: 36126225 Free PMC article. Updated. Review.
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Wong CKH, et al. Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24. Lancet Infect Dis. 2022. PMID: 36029795 Free PMC article.
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Aggarwal NR, et al. Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10. Lancet Infect Dis. 2023. PMID: 36780912 Free PMC article.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Hammond J, et al. N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16. N Engl J Med. 2022. PMID: 35172054 Free PMC article. Clinical Trial.
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA, McLaughlin JM, Malden D, Hong V, Puzniak L, Ackerson BK, Lewin BJ, Kim JS, Shaw SF, Takhar H, Jodar L, Tartof SY. Lewnard JA, et al. Lancet Infect Dis. 2023 Jul;23(7):806-815. doi: 10.1016/S1473-3099(23)00118-4. Epub 2023 Mar 15. Lancet Infect Dis. 2023. PMID: 36933565 Free PMC article.
202 results